Last updated: January 17, 2024
Sponsor: Xuanwu Hospital, Beijing
Overall Status: Active - Recruiting
Phase
N/A
Condition
Atherosclerosis
Treatment
Cold laser plaque ablation
The excimer laser
Clinical Study ID
NCT06211127
ZKRG-PAD-202304
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: General selection criteria
- Age between 18 and 85, gender is not limited;
- Patients with symptomatic lower extremity arteriosclerosis disease (LEAD), Rutherfordgrade 2 to 5;
- The stenosis of lower extremity arteries is greater than 70% or occlusion;
- The subject is able and willing to comply with all requirements, including 6-monthfollow-up and evaluation, voluntary participation and informed consent. Intraoperative contrast inclusion criteria
- The internal diameter of the reference vessel proximal to the target lesion is greaterthan 1.8mm;
- The stenosis of target lesion is greater than 70%;
Exclusion
Exclusion Criteria:
- The target lesion is located in the artificial vascular or autologous venous vascularbypass;
- Endovascular or surgical procedure in the target limb performed less than or equal to 30 days prior to the index procedure OR Planned endovascular or surgical procedure 30days after the index procedure;
- Intent to use other atherectomy device in the same procedure;
- Flow-limiting dissection within, proximal or distal to the target lesion;
- Evidence or history of aneurysm in the target vessel, intracranial or gastrointestinalbleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2months;
- Uncorrected coagulation abnormalities (platelet count ≤ 75*109/ L or INR≥2.0),bleeding constitution, and history of heparin-induced thrombocytopenia (HIT);
- Any thrombolytic therapy was performed within 2 weeks before surgery;
- History of severe trauma, fracture, major surgery, or parenchymal organ biopsy within 2 weeks before surgery;
- Known allergy to contrast agents or perioperative drugs;
- Anticoagulation, antiplatelet or thrombolytic therapy is prohibited;
- Pregnant or lactating women;
- Subjects participating in other clinical trials of drugs or medical devices;
- Other circumstances assessed by the investigator as inappropriate to participate inthe trial.
Study Design
Total Participants: 110
Treatment Group(s): 2
Primary Treatment: Cold laser plaque ablation
Phase:
Study Start date:
October 16, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Xuanwu Hospital, Capital Medical University
Beijing, Beijing 100053
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.